MaxCyte, Inc. Deferred Revenue Recognized
MaxCyte, Inc. (MXCT) reported Deferred Revenue Recognized of $1.69 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-13
- MaxCyte, Inc. contract with customer, liability, revenue recognized for the quarter ending 2026-06-30 was $1.69M, a 17.00% decline year-over-year.
- MaxCyte, Inc. contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was $1.68M, a 29.28% decline year-over-year.
- MaxCyte, Inc. contract with customer, liability, revenue recognized for the quarter ending 2025-09-30 was $1.16M, a 20.83% decline year-over-year.
- MaxCyte, Inc. contract with customer, liability, revenue recognized for the quarter ending 2025-06-30 was $2.04M, a 19.87% decline year-over-year.
- MaxCyte, Inc. contract with customer, liability, revenue recognized for fiscal 2025 was $5.18M, a 3.81% increase from fiscal 2024.
- MaxCyte, Inc. contract with customer, liability, revenue recognized for fiscal 2024 was $4.99M, a 23.27% decline from fiscal 2023.
- MaxCyte, Inc. contract with customer, liability, revenue recognized for fiscal 2023 was $6.51M, a 96471.68% increase from fiscal 2022.
- MaxCyte, Inc. contract with customer, liability, revenue recognized for fiscal 2022 was $6.74K, a 99.86% decline from fiscal 2021.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 3 month as first filed | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 6 month as first filed | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 9 month as first filed | Contract with Customer, Liability, Revenue Recognized 12 month | Contract with Customer, Liability, Revenue Recognized 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.69M 10-Q · filed 2026-08-13 | $3.07M 10-Q · filed 2026-08-13 | ||||||
| 2026-03-31 | $1.68M 10-Q · filed 2026-05-13 | |||||||
| 2025-12-31 | $5.18M 10-K · filed 2026-03-25 | |||||||
| 2025-09-30 | $1.16M 10-Q · filed 2025-11-13 | $4.96M 10-Q · filed 2025-11-13 | ||||||
| 2025-06-30 | $2.04M 10-Q · filed 2026-08-13 | $4.42M 10-Q · filed 2026-08-13 | ||||||
| 2025-03-31 | $2.37M 10-Q · filed 2026-05-13 | |||||||
| 2024-12-31 | $4.99M 10-K · filed 2026-03-25 | |||||||
| 2024-09-30 | $1.46M 10-Q · filed 2025-11-13 | $4.69M 10-Q · filed 2025-11-13 | ||||||
| 2024-06-30 | $2.55M 10-Q · filed 2025-08-06 | $4.06M 10-Q · filed 2025-08-06 | ||||||
| 2024-03-31 | $2.25M 10-Q · filed 2025-05-08 | |||||||
| 2023-12-31 | $6.51M 10-K · filed 2025-03-11 | $6.51K 10-K · filed 2024-03-12 | ||||||
| 2023-09-30 | $1.97M 10-Q · filed 2024-11-06 | $2.00M 10-Q · filed 2023-11-08 | $5.74M 10-Q · filed 2024-11-06 | $5.70M 10-Q · filed 2023-11-08 | ||||
| 2023-06-30 | $2.57M 10-Q · filed 2024-08-06 | $2.60M 10-Q · filed 2023-08-09 | $4.59M 10-Q · filed 2024-08-06 | $4.60M 10-Q · filed 2023-08-09 | ||||
| 2023-03-31 | $2.62M 10-Q · filed 2024-05-07 | $2.60M 10-Q · filed 2023-05-10 | ||||||
| 2022-12-31 | $6.74K 10-K · filed 2024-03-12 | $6.74M 10-K · filed 2023-03-15 | ||||||
| 2022-09-30 | $2.80M 10-Q · filed 2023-11-08 | $5.90M 10-Q · filed 2023-11-08 | ||||||
| 2022-06-30 | $2.70M 10-Q · filed 2023-08-09 | $4.80M 10-Q · filed 2023-08-09 | ||||||
| 2022-03-31 | $2.60M 10-Q · filed 2023-05-10 | |||||||
| 2021-12-31 | $4.83M 10-K · filed 2023-03-15 | |||||||
| 2021-09-30 | $2.60M 10-Q · filed 2022-11-09 | $4.40M 10-Q · filed 2022-11-09 | ||||||
| 2021-06-30 | $1.50M 10-Q · filed 2022-08-10 | $3.50M 10-Q · filed 2022-08-10 | ||||||
| 2021-03-31 | $2.00M 10-Q · filed 2022-05-09 | |||||||
| 2020-12-31 | $3.19M 10-K · filed 2022-03-22 | |||||||
| 2020-09-30 | $1.80M 10-Q · filed 2021-11-10 | $3.00M 10-Q · filed 2021-11-10 | ||||||
| 2020-06-30 | $1.00M 10-Q · filed 2021-09-13 | $2.50M 10-Q · filed 2021-09-13 | ||||||
| 2019-12-31 | $2.44M 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |